DK1007020T3 - 9-cis-retinoidsyre til cellemedierede immunsygdomme - Google Patents

9-cis-retinoidsyre til cellemedierede immunsygdomme

Info

Publication number
DK1007020T3
DK1007020T3 DK98947437T DK98947437T DK1007020T3 DK 1007020 T3 DK1007020 T3 DK 1007020T3 DK 98947437 T DK98947437 T DK 98947437T DK 98947437 T DK98947437 T DK 98947437T DK 1007020 T3 DK1007020 T3 DK 1007020T3
Authority
DK
Denmark
Prior art keywords
cis
pharmaceutically acceptable
retinoic acid
mediated immune
cell
Prior art date
Application number
DK98947437T
Other languages
English (en)
Inventor
Werner Bollag
Fritz Ott
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of DK1007020T3 publication Critical patent/DK1007020T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK98947437T 1997-08-23 1998-08-18 9-cis-retinoidsyre til cellemedierede immunsygdomme DK1007020T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases

Publications (1)

Publication Number Publication Date
DK1007020T3 true DK1007020T3 (da) 2004-06-07

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98947437T DK1007020T3 (da) 1997-08-23 1998-08-18 9-cis-retinoidsyre til cellemedierede immunsygdomme

Country Status (18)

Country Link
US (2) US6589989B1 (da)
EP (2) EP0908179A1 (da)
JP (1) JP3522220B2 (da)
KR (1) KR100596260B1 (da)
CN (1) CN1136845C (da)
AT (1) ATE259224T1 (da)
AU (1) AU739440B2 (da)
BR (1) BRPI9811989B8 (da)
CA (1) CA2301907C (da)
DE (1) DE69821624T2 (da)
DK (1) DK1007020T3 (da)
ES (1) ES2214729T3 (da)
NO (1) NO327141B1 (da)
NZ (1) NZ502812A (da)
PT (1) PT1007020E (da)
RU (1) RU2238083C2 (da)
TR (1) TR200000488T2 (da)
WO (1) WO1999009969A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
AU2004222279B2 (en) 2003-03-14 2010-01-21 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
KR100743278B1 (ko) 2003-04-11 2007-07-26 에프. 호프만-라 로슈 아게 9-시스 레티노산의 제조 방법
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
CN1921843A (zh) * 2004-01-23 2007-02-28 独立行政法人科学技术振兴机构 含视黄酸的糖尿病治疗药
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
SI2397133T1 (sl) * 2004-06-18 2017-12-29 University of Washington Intellectual Property and Technology Transfer Retinalni derivati in metode za njihovo uporabo pri zdravljenju motenj vida
JP5042839B2 (ja) 2005-09-09 2012-10-03 有限会社ケムフィズ 腸疾患の予防及び／又は治療のための医薬
US8324270B2 (en) 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2011132084A2 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
JP6461792B2 (ja) 2012-08-17 2019-01-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ オレフィン化合物の異性化
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (da) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US6083977A (en) * 1994-12-30 2000-07-04 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
US20040039056A1 (en) 2004-02-26
PT1007020E (pt) 2004-05-31
ATE259224T1 (de) 2004-02-15
CA2301907A1 (en) 1999-03-04
AU9435698A (en) 1999-03-16
US6589989B1 (en) 2003-07-08
EP0908179A1 (en) 1999-04-14
DE69821624T2 (de) 2004-09-23
RU2238083C2 (ru) 2004-10-20
BR9811989A (pt) 2000-09-05
NZ502812A (en) 2002-05-31
EP1007020A1 (en) 2000-06-14
JP2003526595A (ja) 2003-09-09
NO20000870L (no) 2000-02-22
JP3522220B2 (ja) 2004-04-26
BRPI9811989B1 (pt) 2015-12-15
ES2214729T3 (es) 2004-09-16
WO1999009969A1 (en) 1999-03-04
CN1136845C (zh) 2004-02-04
BRPI9811989B8 (pt) 2021-05-25
CN1268886A (zh) 2000-10-04
TR200000488T2 (tr) 2000-07-21
KR100596260B1 (ko) 2006-07-03
AU739440B2 (en) 2001-10-11
CA2301907C (en) 2009-02-10
DE69821624D1 (de) 2004-03-18
KR20010023186A (ko) 2001-03-26
NO327141B1 (no) 2009-05-04
NO20000870D0 (no) 2000-02-22
EP1007020B1 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
DK1007020T3 (da) 9-cis-retinoidsyre til cellemedierede immunsygdomme
Windhorst et al. General clinical toxicology of oral retinoids
IE871981L (en) Programmed release formulation.
DE69206345T2 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
NO920740L (no) Doseringsform for oral administrering av hypoglykemisk glipizid
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
EP0414772A4 (en) Method for treating acne
JPH04243825A (ja) 色素沈着症治療剤
KR910005858A (ko) 지방산 요법
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
ATE171375T1 (de) Pharmazeutische zusammensetzung, die als hilfsmittelbehandlung von seborrhoid-dermatitis, auch bei hiv-patienten, verwendbar ist
WO2000026185A3 (en) Omeprazole solution and method of using same
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
AU772148B2 (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US4218445A (en) N,N'Dibenzylethylenediamine-diacetylsalicylate, a novel chemotherapeutic agent for pain relief by external application
王永祥 et al. EFFICACY OF DIETHYLCARBAMAZINE CREAM ON LYMPHATIC FILARIASIS BY TRANSEPIDERMAL APPLICATION
CN1260982A (zh) 入地金牛外用止痛中药
UA36078A (uk) Спосіб комплексного лікування хронічного катарального гінгівіту у дітей, хворих на цукровий діабет